Next generation TKIs are developed to target a broader spectrum of EGFR mutations. But can they overcome the challenges presented by exon 20 insertion mutations?
As expected, the majority of ESMO orals will be IO related. As for small molecules, oral presentations include the usual line up of targets, but also some things new or noteworthy.
With already five EGFR TKIs to choose from, is there room for one more? Janssen thinks there is, betting on a combination strategy to defeat osimertinib
